SCHEMBL5229259

SCHEMBL5229259

CN(C)CCn1c(=O)c2c3cc(OCCO)ccc3c3c(oc4ccccc4n3C(=O)OC(C)(C)C)c2c1=O

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.43
SIGMAR1 Q99720 12/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
KMT2A Q03164 1/20 0.34
CSF1R P07333 2/20 0.34
KDR P35968 1/20 0.34
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5452569 0.91 NR1H2 (0.34) NR1H2SIGMAR1L3MBTL1KMT2ACSF1R
SCHEMBL5233887 0.87 HTR6 (0.41) SIGMAR1L3MBTL1ALDH1A1MAPT
SCHEMBL5421563 0.83 SIGMAR1 (0.38) SIGMAR1L3MBTL1KMT2ACSF1RKDR
SCHEMBL5233411 0.80 G6PD (0.40) L3MBTL1KMT2AALDH1A1
SCHEMBL5226141 0.77 SIGMAR1 (0.39) SIGMAR1
SCHEMBL5231971 0.69 ALDH1A1 (0.34) SIGMAR1KMT2AALDH1A1HPGD
SCHEMBL5228985 0.67 MAOA (0.35) SIGMAR1
SCHEMBL5318072 0.66 MAOA (0.37) SIGMAR1L3MBTL1KMT2AKDR
SCHEMBL5226351 0.61 MPO (0.40)
SCHEMBL27165276 0.61 TOP2A (0.52) SIGMAR1L3MBTL1KMT2AALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312213-B2 Substituted benzo[e][1,4]oxazino[3,2-g]isoindole compounds LES LABORATORIES SERVIER (FR) 2007-12-25 US disclosed
EP-1556387-B1 SUBSTITUTED BENZOL E| 1,4| OXAZINO 3,2-G| ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2007-04-04 EP disclosed
US-20060003997-A1 Substituted benzo[e] [1,4] oxazino [3,2-g] isoindole compounds LES LABORATOIRES SERVIER (FR) 2006-01-05 US disclosed
EP-1556387-A1 SUBSTITUTED BENZOL E] 1,4] OXAZINO 3,2-G] ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier (FR) 2005-07-27 EP disclosed
WO-2004037830-A1 SUBSTITUTED BENZOL[E] [1,4] OXAZINO[3,2-G] ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060003997-A1 Substituted benzo[e] [1,4] oxazino [3,2-g] isoindole compounds H1-3, H1-0, H1-2 NR1H2 483/4885SIGMAR1 210/4885L3MBTL1 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.